Cue Biopharma, a clinical-stage biopharmaceutical company, announced a $50 million private placement by selling 1.4 million shares and pre-funded warrants to accredited investors at about $33.21 per share. The funding, led by Cormorant Asset Management and including Columbia Threadneedle Investments, will support Cue's clinical development and general corporate needs. The company is advancing therapies targeting functional cures for immunological disorders, with upcoming clinical data expected by Q3 2026. The private placement is expected to close around July 13, 2026, subject to customary conditions.
On July 8, 2026, Cathie Wood sold $8 million of Advanced Micro Devices (AMD) stock in a single day. This significant sale by a well-known investor could indicate a shift in her portfolio strategy or a response to market conditions affecting AMD. Inve...
The inaugural Juneteenth Exchange summit in Rancho Cordova gathered over 150 leaders from business, technology, and investment sectors to discuss innovation, economic opportunity, and inclusive leadership. The event highlighted the city's growing app...
SKYAI surged 216% in mid-June from $0.151 to $0.479 but then plunged 92% due to heavy selling by large holders (whales) during price bounces, raising concerns of market manipulation. On-chain data and researchers highlight a pattern of concentrated s...
In Q2 2026, public companies purchased 110,000 Bitcoin, nearly doubling their Bitcoin acquisitions from the previous two quarters combined. Corporate treasuries now hold over 1.26 million BTC, representing more than 6% of Bitcoin's total supply. This...
Canon U.S.A., Inc. has been awarded the 2026-2028 Most Energy Efficient Toner-Based A3 and A4 Brand Awards by Keypoint Intelligence, recognizing its commitment to energy-conscious printer design. The awards are based on a new testing methodology eval...
